Translating the Preclinical Pharmacology of the Select TLR8 Agonist VTX-2337, into Clinical Activity using Rules-Based Medicine, a Q2 Solutions Company (formerly Myriad RBM) InflammationMAP
VTX-2337 is a selective TLR8 agonist that activates myeloid dendritic cells, monocytes and NK cells to produce both chemokines and Th1 polarizing cytokines. Prior to the conduct of clinical studies in cancer patients, the RBM InflammationMAP® was used to compare the potency of VTX-2337 on human and non-human primate leukocyte populations, and define pharmacokinetic/pharmacodynamic relationship in cynomolgus monkeys. This characterization defined potential clinical biomarkers of VTX-2337 activity and established a Minimal Anticipated Biological Effect Level (MABEL) for the initial clinical trial.
Gregory N. Dietsch, Ph.D., DABT
Dr. Gregory N Dietsch, Ph.D., DABT, currently serves as Vice President of Research at VentiRx Pharmaceuticals. Prior to joining VentiRx, Dr. Dietsch was Vice President of Preclinical Sciences at ICOS Corporation, where he built and directed the pharmacology, drug metabolism, pathology and toxicology groups that supported ICOS Research and Clinical development programs.
- Compare potency
- Define PK/PD relationships
- Identify potential clinical biomarkers of VTX-2337 activity
- Establish a Minimal Anticipated Biological Effect Level (MABEL) for the initial clinical trial
Researchers interested in the application of biomarkers in the following fields:
- Translational Medicine
- 09 Apr 2013
- Inflammation, TruCulture, TruCulture Webinars, Webinars